Cargando…

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer

Detalles Bibliográficos
Autores principales:	Arend, Rebecca C., Londoño-Joshi, Angelina I., Gangrade, Abhishek, Katre, Ashwini A., Kurpad, Chandrika, Li, Yonghe, Samant, Rajeev S., Li, Pui-Kai, Landen, Charles N., Yang, Eddy S., Hidalgo, Bertha, Alvarez, Ronald D., Straughn, John Michael, Forero, Andres, Buchsbaum, Donald J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922410/ https://www.ncbi.nlm.nih.gov/pubmed/29721216 http://dx.doi.org/10.18632/oncotarget.25151

Ejemplares similares

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2016)

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth
por: Turner, Taylor B, et al.
Publicado: (2017)

SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma
por: Jordan Montgomery, Emma, et al.
Publicado: (2023)

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review
por: Smith, Haller J., et al.
Publicado: (2017)

The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/β-Catenin Signaling in Cancer Cells
por: Lin, Cuihong, et al.
Publicado: (2013)

Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2
por: Li, Rui, et al.
Publicado: (2023)

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
por: Kang, Borui, et al.
Publicado: (2023)

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
por: Doo, David W., et al.
Publicado: (2020)

The magic bullet: Niclosamide
por: Jiang, Haowen, et al.
Publicado: (2022)

Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
por: Shamim, Khalida, et al.
Publicado: (2021)

The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR
por: Kao, Jo-Chi, et al.
Publicado: (2018)

Niclosamide: Beyond an antihelminthic drug
por: Chen, Wei, et al.
Publicado: (2018)

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
por: McCaw, Tyler R., et al.
Publicado: (2020)

Binding interactions of niclosamide with serum proteins
por: Maltas, Esra
Publicado: (2014)

Niclosamide for Covid-19: bridging the gap
por: Al-kuraishy, Hayder M., et al.
Publicado: (2021)

Antitumor effect and metabonomics of niclosamide micelles
por: Hang, Jiarong, et al.
Publicado: (2022)

Synthesis and biological evaluation of niclosamide PROTACs
por: Munoz, Erick, et al.
Publicado: (2022)

Repurposing niclosamide for the treatment of neurological disorders
por: Apolloni, Savina, et al.
Publicado: (2023)

Desolvation Processes in Channel Solvates of Niclosamide
por: Mann, Jen E., et al.
Publicado: (2023)

Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway
por: Lu, Wenyan, et al.
Publicado: (2011)

Niclosamide Is Active In Vitro against Mycetoma Pathogens
por: Mahmoud, Abdelhalim B., et al.
Publicado: (2021)

Niclosamide—A promising treatment for COVID‐19
por: Singh, Shivani, et al.
Publicado: (2022)

Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori
por: Tharmalingam, Nagendran, et al.
Publicado: (2018)

Niclosamide Triggers Non-Canonical LC3 Lipidation
por: Liu, Yajun, et al.
Publicado: (2019)

Antihelminthic niclosamide modulates dendritic cells activation and function
por: Wu, Chieh-Shan, et al.
Publicado: (2014)

Niclosamide encapsulated polymeric nanocarriers for targeted cancer therapy
por: Jain, Nishant Kumar, et al.
Publicado: (2019)

Study on the Synergistic Molluscicidal Effect of Pedunsaponin A and Niclosamide
por: Yang, Chunping, et al.
Publicado: (2022)

Niclosamide potentiates TMEM16A and induces vasoconstriction
por: Liang, Pengfei, et al.
Publicado: (2023)

Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway
por: Tomizawa, Minoru, et al.
Publicado: (2013)

Niclosamide inhibits leaf blight caused by Xanthomonas oryzae in rice
por: Kim, Sung-Il, et al.
Publicado: (2016)

Migration and Transformation Characteristics of Niclosamide in a Soil–Plant System
por: Luo, Cui, et al.
Publicado: (2018)

Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia
por: Hamdoun, Sami, et al.
Publicado: (2017)

Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer
por: Lin, Chi-Kang, et al.
Publicado: (2016)

Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
por: Oh, Hyeong-Cheol, et al.
Publicado: (2020)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
por: Andersen, Petter I., et al.
Publicado: (2019)

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
por: Pindiprolu, Sai Kiran S.S., et al.
Publicado: (2020)

Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
por: Shangguan, Fugen, et al.
Publicado: (2020)

Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy
por: Kim, Hyun-Jun, et al.
Publicado: (2021)

Niclosamide is a potential candidate for the treatment of chemo-resistant osteosarcoma
por: Huang, Xiaoling, et al.
Publicado: (2023)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s3kaesghh97u6h2ea84eqk6k65